Evidence map›Paper›PMID 31391235›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2019

Recognition of Class II MHC Peptide Ligands That Contain β-Amino Acids.

Ross W Cheloha, Andrew W Woodham, Djenet Bousbaine, Tong Wang, Shi Liu, John Sidney, Alessandro Sette, Samuel H Gellman, Hidde L Ploegh

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Exploring cellular biochemistry with nanobodies.The Journal of biological chemistry · 2020
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ross W ChelohaBoston Children's Hospital and Harvard Medical School, Boston, MA 02115.ORCID 0000-0001-9871-8333
Andrew W WoodhamBoston Children's Hospital and Harvard Medical School, Boston, MA 02115.
Djenet BousbaineBoston Children's Hospital and Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-2683-9544
Tong WangDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI 53706.ORCID 0000-0003-4208-5578
Shi LiuDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI 53706.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; and.ORCID 0000-0002-0987-405X
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037; and.ORCID 0000-0001-7013-2250
Samuel H GellmanDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI 53706; gellman@chem.wisc.edu hidde.ploegh@childrens.harvard.edu.ORCID 0000-0001-5617-0058
Hidde L PloeghBoston Children's Hospital and Harvard Medical School, Boston, MA 02115; gellman@chem.wisc.edu hidde.ploegh@childrens.harvard.edu.ORCID 0000-0002-1090-6071
Boston Children's Hospital · USUniversity of Wisconsin–Madison · USLa Jolla Institute for Immunology · US

Funding

BIOTECHNOLOGY TRAINING PROGRAMT32GM008349 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FOX, BRIAN G · 1989 to 2019
$22.5M
Protein Recognition by Peptidic FoldamersR01GM056414 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI GELLMAN, SAMUEL H. · 1997 to 2023
$6.5M
Sortase-mediated protein engineering for the study of host-pathogen interactionsR01AI087879 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI PLOEGH, HIDDE L. · 2010 to 2019
$4.5M
NIAID NIH HHS HHSN272201400045CNIAID NIH HHS R01 AI087879NIGMS NIH HHS R01 GM056414NIGMS NIH HHS T32 GM008349
6 · The paper itself

Abstract

Proteins are composed of α-amino acid residues. This consistency in backbone structure likely serves an important role in the display of an enormous diversity of peptides by class II MHC (MHC-II) products, which make contacts with main chain atoms of their peptide cargo. Peptides that contain residues with an extra carbon in the backbone (derived from β-amino acids) have biological properties that differ starkly from those of their conventional counterparts. How changes in the structure of the peptide backbone affect the loading of peptides onto MHC-II or recognition of the resulting complexes by TCRs has not been widely explored. We prepared a library of analogues of MHC-II-binding peptides derived from OVA, in which at least one α-amino acid residue was replaced with a homologous β-amino acid residue. The latter contain an extra methylene unit in the peptide backbone but retain the original side chain. We show that several of these α/β-peptides retain the ability to bind tightly to MHC-II, activate TCR signaling, and induce responses from T cells in mice. One α/β-peptide exhibited enhanced stability in the presence of an endosomal protease relative to the index peptide. Conjugation of this backbone-modified peptide to a camelid single-domain Ab fragment specific for MHC-II enhanced its biological activity. Our results suggest that backbone modification offers a method to modulate MHC binding and selectivity, T cell stimulatory capacity, and susceptibility to processing by proteases such as those found within endosomes where Ag processing occurs.

Indexed as

Amino AcidsAmino Acid SequenceAnimalsBinding SitesCell Line, TumorGenes, MHC Class IIHistocompatibility Antigens Class IILigandsMicePeptide FragmentsProtein BindingReceptors, Antigen, T-CellStructure-Activity RelationshipT-LymphocytesAmino AcidsHistocompatibility Antigens Class IILigandsPeptide FragmentsReceptors, Antigen, T-Cell

Identifiers

PMID31391235
PMCPMC6736755
OpenAlexW2966487248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.